z-logo
open-access-imgOpen Access
Imatinib: Time to Rethink 400 mg Starting Dose?
Author(s) -
Robert H. Carlson
Publication year - 2010
Publication title -
oncology times
Language(s) - English
Resource type - Journals
eISSN - 1548-4688
pISSN - 0276-2234
DOI - 10.1097/01.cot.0000368426.42926.06
Subject(s) - imatinib , medicine , imatinib mesylate , myeloid leukemia , chronic myelogenous leukemia , hematology , tyrosine kinase inhibitor , gastroenterology , leukemia , cancer

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom